Journal of drug targeting
Mitigating doxorubicin-induced toxicity in breast cancer treatment with in situ pH-sensitive carvedilol-loaded transbilosomes: in vitro and in vivo characterization.
Tamer Mohamed Mahmoud, Mohammed Ayad Alboreadi, Fatma I Abo El-Ela, Amr Gamal Fouad, Mary Girgis Shahataa, Amany Belal, Fahad H Baali, Nisreen Khalid Aref Albezrah, Mohammed S Alharthi, Sherif Faysal Abdelfattah Khalil, Rana El-Bakry
Published: 202510.1080/1061186X.2025.2599403
Abstract
Doxorubicin (DRC) is widely used as a breast cancer treatment. However, its use is limited due to cardio, hepatic, and renal toxicities. Carvedilol (CVL) has emerged as a potential protective agent against DRC-induced toxicity (DIT). Despite this, CV…
Preview only. Read the full abstract at the source